Merck's HIV Prevention Pill Could Cost Just $5 Per Year

An experimental pill that protects against HIV infection could be mass produced for less than five dollars per person each year, offering hope to millions at risk of contracting the virus.

Merck's drug, called MK 8527, is currently in late-stage clinical trials with results expected in late 2027. Early studies show the pill works quickly, potentially protecting people within just 24 hours of taking it.

The drug works as pre-exposure prophylaxis, or PrEP, meaning people at high risk of HIV infection take it before potential exposure. Unlike current prevention methods, this new pill uses a novel approach that researchers say could make it more effective and easier to use.

Mid-stage trial results released last summer showed the drug is both safe and effective at preventing infection. The promising data has already generated significant interest from public health advocates and medical professionals worldwide.

The Ripple Effect

The real game changer is the price tag. Researchers found the pill could be manufactured for under $5 per patient annually, making it affordable even in the world's poorest countries.

This low production cost means Merck could license the drug to generic manufacturers in low and middle-income nations without losing money. Advocates are already calling on the company to do exactly that, ensuring the people who need it most can access it.

Currently, about 38 million people worldwide live with HIV, and many more remain at high risk of infection. Access to affordable prevention could dramatically reduce new infections, particularly in Africa and Asia where HIV rates remain highest.

The drug's quick action time also sets it apart. Traditional PrEP medications can take days or weeks to reach full protective levels, but this pill works within a day of the first dose.

If the late-stage trials confirm the earlier results, the drug could receive regulatory approval by 2028. From there, licensing agreements and manufacturing partnerships would determine how quickly it reaches the people who need it most.

The combination of effectiveness, speed, and affordability represents exactly what global health experts have been hoping for in HIV prevention technology. It's a reminder that medical breakthroughs can happen when innovation meets accessibility, creating solutions that work for everyone, not just those who can afford premium healthcare.